These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24124391)

  • 1. The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival.
    Tantraworasin A; Saeteng S; Lertprasertsuke N; Arayawudhikul N; Kasemsarn C; Patumanond J
    Cancer Manag Res; 2013; 5():327-36. PubMed ID: 24124391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
    Shi Y; Chen L; Li J; Lü YL; Jiao SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.
    Huang ZL; Cao X; Luo RZ; Chen YF; Zhu LC; Wen Z
    Oncol Lett; 2016 Jan; 11(1):299-305. PubMed ID: 26870207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
    Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
    Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zhao H; Zhang H; Du Y; Gu X
    Tumour Biol; 2014 Dec; 35(12):12679-88. PubMed ID: 25227663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
    Lafuente-Sanchis A; Zúñiga Á; Galbis JM; Cremades A; Estors M; Martínez-Hernández NJ; Carretero J
    Clin Transl Oncol; 2016 Aug; 18(8):798-804. PubMed ID: 26542178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
    Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
    Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of the mRNA expression of
    Sun S; Shi W; Wu Z; Zhang G; Yang BO; Jiao S
    Exp Ther Med; 2015 Sep; 10(3):937-941. PubMed ID: 26622418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic Analysis of ERCC1, RRM1 and p53 Expressions in Postoperative Stage I-II Lung Cancer.].
    Wang H; Feng J; Zhang X; Yang X; He W; Sha H; Han B
    Zhongguo Fei Ai Za Zhi; 2009 May; 12(5):387-95. PubMed ID: 20719132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
    Leng XF; Chen MW; Xian L; Dai L; Ma GY; Li MH
    J Exp Clin Cancer Res; 2012 Mar; 31(1):25. PubMed ID: 22439756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer.
    Wang X; Zhao J; Yang L; Mao L; An T; Bai H; Wang S; Liu X; Feng G; Wang J
    Med Oncol; 2010 Jun; 27(2):484-90. PubMed ID: 19488864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
    Su C; Zhou S; Zhang L; Ren S; Xu J; Zhang J; Lv M; Zhang J; Zhou C
    Med Oncol; 2011 Dec; 28(4):1411-7. PubMed ID: 20467918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
    Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Maithel SK
    Cancer; 2013 Jan; 119(2):445-53. PubMed ID: 22569992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of tumor recurrence in completely resected non-small cell lung cancer.
    Tantraworasin A; Saeteng S; Lertprasertsuke N; Arreyakajohn N; Kasemsarn C; Patumanond J
    Cancer Manag Res; 2013; 5():77-84. PubMed ID: 23785244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
    Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
    Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
    Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
    Simon GR; Schell MJ; Begum M; Kim J; Chiappori A; Haura E; Antonia S; Bepler G
    Cancer; 2012 May; 118(9):2525-31. PubMed ID: 22028294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiation.
    Shilkrut M; Wu A; Thomas DG; Hamstra DA
    Mol Clin Oncol; 2014 May; 2(3):479-487. PubMed ID: 24772321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERCC1, RRM1 and TUBB3 mRNA expression on the tumor response and overall survival of non-small cell lung cancer treated with platinum-based chemotherapy.
    Qiao H; Huang X; Guo H; Liu Y; Yue C
    Pak J Med Sci; 2014; 30(6):1403-8. PubMed ID: 25674147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of Expression of ERCC1, RRM1 on Survival Trend of Lung Cancer with Cisplatin Combine Gemcitabine Chemotherapy after Surgical Resection.].
    Liang W; Hu C; Gu Q; Song M; Luo W
    Zhongguo Fei Ai Za Zhi; 2009 May; 12(5):403-7. PubMed ID: 20719134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.